Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy:: An [18F]Fallypride PET study

被引:69
|
作者
Werhahn, Konrad J.
Landvogt, Christian
Klimpe, Sven
Buchholz, Hans-Georg
Yakushev, Igor
Siessmeier, Thomas
Mueller-Forell, Wibke
Piel, Markus
Roesch, Frank
Glaser, Martin
Schreckenberger, Mathias
Bartenstein, Peter
机构
[1] Univ Mainz, Dept Neurol, D-55101 Mainz, Germany
[2] Univ Mainz, Dept Neurosurg, D-55101 Mainz, Germany
[3] Univ Mainz, Dept Nucl Med, D-55101 Mainz, Germany
[4] Univ Mainz, Inst Neuroradiol, D-55101 Mainz, Germany
[5] Univ Mainz, Dept Nucl Chem, D-55101 Mainz, Germany
关键词
D O I
10.1111/j.1528-1167.2006.00561.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Although animal data are suggestive, evidence for an alteration of the extrastriatal dopaminergic system in human focal epilepsy is missing. Methods: To quantify D2/D3-receptor density, we studied seven patients with temporal lobe epilepsy (TLE) and nine age-matched controls with positron emission tomography (PET) by using the high-affinity dopamine D2/D3-receptor ligand [F-18]Fallypride ([F-18]FP) suitable for imaging extrastriatal binding. TLE was defined by interictal and ictal video-EEG, magnetic resonance imaging (MRI), and [F-18]fluorodeoxyglucose ([F-18]FDG)-PET and was due to hippocampal sclerosis (HS), based on histology in all patients. Primary analysis was based on regions of interest (ROIs) defined on individual MRIs. For each patient, binding potential (BP) was calculated by using the simplified reference tissue model, and the epileptogenic was compared with the unaffected hemisphere in each ROI. To confirm the results, an additional voxel-based group analysis was performed by using statistical parametric mapping. Results: Compared with controls, [F-18]FP BP was significantly decreased in the epileptogenic temporal lobe in all patients. On ROI analysis, this reduction was evident in areas surrounding the seizure-onset zone at the pole (-34.2%) and lateral aspects (-32.9%) of the temporal lobe. Although the hippocampus [F-18]FDG uptake (-8.1%) and hippocampal MR volume (-35.1%) were significantly reduced, no significant decrease of [F-18]FP BP was found. Reduction of [F-18]FP BP did not correlate with hippocampal atrophy. Conclusions: D2/D3-receptor binding is reduced at the pole and in lateral aspects of the epileptogenic temporal lobe in patients with mesial TLE and HS. This area might correspond to "the irritative zone," indicating that D2/D3 receptors might play a specific role in the pathophysiology of mesial TLE.
引用
收藏
页码:1392 / 1396
页数:5
相关论文
共 50 条
  • [31] Cerebral morphology and dopamine D2/D3 receptor distribution in humans: A combined 18F fallypride and voxel-based morphometry study
    Woodward, Neil D.
    Zald, David H.
    Li, Rui
    Riccardi, Patrizia
    Ansari, M. Sib
    Dawant, Benoit
    Anderson, Sharlet
    Baldwin, Ronald
    Kessler, Robert M.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 12S - 12S
  • [32] High-throughput rat brain PET imaging and automatic spatial normalization of the dopamine D2/3 receptor ligand [18F]fallypride
    Lange, D.
    Tejada, I. M.
    Xiong, M.
    Hillebrand, B.
    Noergaard, M.
    Baerentzen, S.
    Shalgunov, V.
    Herth, M. M.
    Svarer, C.
    Palner, M.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2019, 39 : 588 - 589
  • [33] 18F-Fallypride PET and D2/3 Receptors in PD
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 15N - 15N
  • [34] Occupancy of dopamine D2 receptors by aripiprazole at steady state dosing in schizophrenia measured with [18F]fallypride PET
    Frankle, WG
    Narendran, R
    Gil, R
    Hwang, DR
    Hwang, YY
    Scher, E
    Cangiano, C
    Laruelle, M
    Abi-Dargham, A
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 219S - 219S
  • [35] Evaluation of dopamine D3 receptor binding of 18F-fallypride
    Jerjian, Taleen
    Constantinescu, Cristian
    Sevrioukov, Evgueni
    Mukherjee, Jouesh
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [36] Therapeutic Occupancy of the D2/3-Preferring Dopamine Receptor Agonist Pramipexol in Brains of Patients with Parkinson's Disease ([18F]-Fallypride PET Study)
    Deutschlander, Angela
    La Fougere, Christian
    Xiong, Guoming
    Boetzel, Kai
    Gruender, Gerhard
    Cumming, Paul
    NEUROLOGY, 2012, 78
  • [37] Therapeutic occupancy of the D2/3-preferring dopamine receptor agonist pramipexol in brains of patients with Parkinson's disease ([18F]-fallypride PET study)
    Deutschlaender, A.
    Boetzel, K.
    La Fougere, C.
    Xiong, G.
    Gruender, G.
    Cumming, P.
    MOVEMENT DISORDERS, 2013, 28 : S64 - S65
  • [38] Cerebral morphology and dopamine D2/D3 receptor distribution in humans: A combined [18F] fallypride and voxel-based morphometry study
    Woodward, Neil D.
    Zald, David H.
    Ding, Zhaohua
    Riccardi, Patrizia
    Ansari, M. Sib
    Baldwin, Ronald M.
    Cowan, Ronald L.
    Li, Rui
    Kessler, Robert M.
    NEUROIMAGE, 2009, 46 (01) : 31 - 38
  • [39] α2-Adrenergic Drugs Modulate the Binding of [18F]Fallypride to Dopamine D2/3 Receptors in Striatum of Living Mouse
    Rominger, Axel
    Mille, Erik
    Boning, Guido
    Wangler, Bjorn
    Gildehaus, Franz Josef
    Arszol, Cornelia
    Bartenstein, Peter
    Cumming, Paul
    SYNAPSE, 2010, 64 (08) : 654 - 657
  • [40] Occupancy of dopamine D2 receptors by aripiprazole at steady state dosing in schizophrenia measured with [18F] fallypride PET
    Frankle, WG
    Narendran, R
    Gil, R
    Hwang, DR
    Hwang, YY
    Scher, E
    Cangiano, C
    Laruelle, M
    Abi-Dargham, A
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S116 - S116